From what 4 stock analysts predict, the share price for Guardant Health Inc (GH) might increase by 75.04% in the next year. This is based on a 12-month average estimation for GH. Price targets go from $19 to $50. The majority of stock analysts believe GH is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Guardant Health Inc has a total of 4 Wall St Analyst ratings. There are 4 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Guardant Health Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of GH.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Eve Burstein Bernstein | Outperform | $35 | Maintains | Oct 30, 2024 |
Leerink Partners | Outperform | $50 | Maintains | Oct 17, 2024 |
Dan Leonard UBS | Buy | $40 | Maintains | Aug 21, 2024 |
David Westenberg Piper Sandler | Overweight | $34 | Maintains | Aug 13, 2024 |
Julia Qin JP Morgan | Overweight | $48 | Maintains | Aug 8, 2024 |
Alex Nowark Craig-Hallum | Buy | $37 | Maintains | Aug 8, 2024 |
Patrick Donnelly Citigroup | Buy | $45 | Maintains | Aug 8, 2024 |
Dan Brennan TD Cowen | Buy | $42 | Maintains | Aug 8, 2024 |
Mark Massaro BTIG | Buy | $50 | Maintains | Jul 30, 2024 |
Michael Ryskin B of A Securities | Buy | $40 | Maintains | Jul 18, 2024 |
Matthew Sykes Goldman Sachs | Buy | $32 | Maintains | Jul 17, 2024 |
Subbu Nambi Guggenheim | Buy | $36 | Upgrade | Jun 28, 2024 |
Kyle Mikson Canaccord Genuity | Buy | $38 | Maintains | Jun 4, 2024 |
Tycho Peterson Jefferies | Buy | $32 | Initiates | Jun 3, 2024 |
Mason Carrico Stephens & Co. | Overweight | $44 | Reiterates | May 24, 2024 |
Kyle Mikson Canaccord Genuity | Buy | $30 | Maintains | Apr 29, 2024 |
Alex Nowark Craig-Hallum | Buy | $28 | Assumes | Apr 24, 2024 |
Matthew Sykes Goldman Sachs | Buy | $28 | Maintains | Apr 15, 2024 |
Subbu Nambi Guggenheim | Neutral | Reiterates | Apr 5, 2024 | |
David Westenberg Piper Sandler | Overweight | $30 | Maintains | Feb 26, 2024 |
When did it IPO
2018
Staff Count
1,768
Country
United States
Sector/Industry
Healthcare/Diagnostics & Research
CEO
Dr. Helmy Eltoukhy Ph.D.
Market Cap
$2.69B
In 2023, GH generated $563.9M in revenue, which was a increase of 25.45% from the previous year. This can be seen as a signal that GH's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Free publicity can significantly boost sales for new products, indicating a potential positive impact on revenue and market visibility for companies launching such items.
Why It Matters - Free publicity can significantly boost sales, impacting revenue projections and market perception, which may lead to stock price increases for companies involved.
Summary - Guardant Health (GH) is not expected to meet key criteria for a positive earnings report in its upcoming release. Investors should be prepared for this potential outcome.
Why It Matters - Guardant Health's potential earnings miss could lead to a drop in stock price, signaling weak performance and impacting investor sentiment and confidence in the company's future.
Summary - Guardant Health's blood-based colorectal cancer screening product, Shield, has been named in TIME's annual list of the Best Inventions, recognizing its impact in precision oncology.
Why It Matters - Guardant Health's inclusion in TIME's Best Inventions highlights its innovation and credibility in oncology, potentially boosting investor confidence and interest in the companyโs future growth.
Summary - Guardant Health will present data on blood-based testing's impact on colorectal cancer screening adherence at the ACG 2024 Annual Meeting in Philadelphia, Oct. 25-30, 2024.
Why It Matters - Guardant Health's presentation on blood-based cancer testing could enhance its market position and drive demand for its products, potentially boosting stock performance and investor interest.
Summary - Guardant Health appointed Roberto A. Mignone, Founder of Bridger Management LLC, to its board of directors, effective immediately, enhancing its healthcare expertise.
Why It Matters - Roberto Mignone's appointment to Guardant Health's board enhances strategic insights and governance, potentially boosting investor confidence and impacting stock performance.
Summary - Guardant Health, Inc. (Nasdaq: GH) will report Q3 2024 financial results on November 6, 2024, after market close, with a conference call at 1:30 PM PT. Webcast available on their website.
Why It Matters - Guardant Health's upcoming financial results announcement could impact stock performance, providing insights into growth, profitability, and market position in precision oncology.